HDAC9 and amyotrophic lateral sclerosis: In conclusion, FUS acetylation through HDAC inhibitors is presented as potential therapeutic strategy for FUS-ALS (Figure 4), although the exact underlying relationship between HDACs and FUS pathology is not yet clear.